The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Some biotechnology companies, such as CRISPR Therapeutics (NASDAQ: CRSP), hope to use gene editing technology to treat, or even cure, diseases that existing drugs cannot. CRISPR Therapeutics ...

The research team says, "Until now, CRISPR wasn't used for cancer because it was assumed that knocking out a single gene ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

The medical promise of CRISPR gene editing can be seen most easily in current research on oral cancer, which affects more than 50,000 Americans every year. An increasing challenge in the treatment ...

The CRISPR-Cas gene scissors offer a wide range ... of Wulf Blankenfeldt at HZI have joined forces to decipher the structure ...

Our group applies structural (cryo-EM, x-ray crystallography and NMR), biochemical and biophysical methods together with functional studies to investigate macromolecular-mediated recognition, ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...